Obesity-driven thyroid cancer burden in middle-aged and older populations: temporal trends and projected trajectories based on the Global Burden of Disease study.
[INTRODUCTION] High body mass index (BMI) in middle-aged and older individuals (≥40 years) is a leading risk factor for thyroid cancer-related morbidity and mortality; however, the quantifiable impact
APA
Jiang B, Li J, et al. (2026). Obesity-driven thyroid cancer burden in middle-aged and older populations: temporal trends and projected trajectories based on the Global Burden of Disease study.. Hong Kong medical journal = Xianggang yi xue za zhi, 32(2), 135-143. https://doi.org/10.12809/hkmj2513477
MLA
Jiang B, et al.. "Obesity-driven thyroid cancer burden in middle-aged and older populations: temporal trends and projected trajectories based on the Global Burden of Disease study.." Hong Kong medical journal = Xianggang yi xue za zhi, vol. 32, no. 2, 2026, pp. 135-143.
PMID
41986900
Abstract
[INTRODUCTION] High body mass index (BMI) in middle-aged and older individuals (≥40 years) is a leading risk factor for thyroid cancer-related morbidity and mortality; however, the quantifiable impact of elevated BMI on disability-adjusted life years (DALYs) and mortality in ageing populations remains underexplored. This study comprehensively evaluated the global burden of thyroid cancer attributable to elevated BMI by integrating past epidemiological trends, demographic variability and risk attribution models, and provided relevant projected trajectories using data from the Global Burden of Disease (GBD) study.
[METHODS] We analysed mortality, DALYs, years of life lost (YLLs) and years lived with disability (YLDs). Temporal trends in disease burden from 1990 to 2021 were examined using linear regression models. Cluster analysis was used to assess region-specific burdens across GBD study regions. Finally, projections of future disease burden from 2022 to 2050 were generated using autoregressive integrated moving average and exponential smoothing models.
[RESULTS] In 2021, high BMI contributed to 5255 thyroid cancer-related deaths (age-standardised mortality rate: 0.06 per 100 000) and 144 955 DALYs (age-standardised rate: 1.68 per 100 000); women and low-middle Socio-demographic Index regions were identified as high-risk subgroups. Projections indicate continued increases in mortality and overall disease burden through 2050.
[CONCLUSION] Substantial geographical heterogeneity in thyroid cancer burden was observed across GBD regions. Interventions targeting high-risk demographic groups and regions should be prioritised to reduce this growing disease burden.
[METHODS] We analysed mortality, DALYs, years of life lost (YLLs) and years lived with disability (YLDs). Temporal trends in disease burden from 1990 to 2021 were examined using linear regression models. Cluster analysis was used to assess region-specific burdens across GBD study regions. Finally, projections of future disease burden from 2022 to 2050 were generated using autoregressive integrated moving average and exponential smoothing models.
[RESULTS] In 2021, high BMI contributed to 5255 thyroid cancer-related deaths (age-standardised mortality rate: 0.06 per 100 000) and 144 955 DALYs (age-standardised rate: 1.68 per 100 000); women and low-middle Socio-demographic Index regions were identified as high-risk subgroups. Projections indicate continued increases in mortality and overall disease burden through 2050.
[CONCLUSION] Substantial geographical heterogeneity in thyroid cancer burden was observed across GBD regions. Interventions targeting high-risk demographic groups and regions should be prioritised to reduce this growing disease burden.
MeSH Terms
Humans; Female; Thyroid Neoplasms; Male; Middle Aged; Aged; Global Burden of Disease; Body Mass Index; Disability-Adjusted Life Years; Obesity; Risk Factors; Aged, 80 and over; Quality-Adjusted Life Years; Adult; Cost of Illness
같은 제1저자의 인용 많은 논문 (5)
- Long-term follow-up of predominantly Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukemia in the phase 3 COMMODORE trial.
- Correction to: Long-term follow-up of predominantly Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukemia in the phase 3 COMMODORE trial.
- AI performance for nodule volume doubling time in the follow-up of the UKLS lung cancer screening study compared to expert consensus and histological validation.
- Indolent NK-Cell Lymphoproliferative Disorder of the Nasal Cavity: A Case Report and Review of the Literature.
- Letter to the editor 1 on "MET promotes hepatocellular carcinoma development through the promotion of TRIB3-mediated FOXO1 degradation".